

# Bhaskar Dasgupta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5040232/publications.pdf>

Version: 2024-02-01

133  
papers

9,023  
citations

81434

41  
h-index

49824

91  
g-index

138  
all docs

138  
docs citations

138  
times ranked

5332  
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia" by Evangelatos et al. Annals of the Rheumatic Diseases, 2023, 82, e43-e43.	0.5	3
2	Response to: "Halo Score"™: missing large vessel giant cell arteritis" do we need a modified "Halo Score"™ by Chattopadhyay and Ghosh. Annals of the Rheumatic Diseases, 2022, 81, e119-e119.	0.5	4
3	Response to: "Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care"™ by Molina Collada et al. Annals of the Rheumatic Diseases, 2022, 81, e176-e176.	0.5	3
4	Response to: "Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues"™ by Ghajari and Sabour. Annals of the Rheumatic Diseases, 2022, 81, e106-e106.	0.5	2
5	Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis. Journal of Clinical Rheumatology, 2022, 28, e297-e300.	0.5	9
6	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology, 2022, 61, 2915-2922.	0.9	24
7	Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. Rheumatology, 2022, , .	0.9	1
8	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 653-661.	0.5	49
9	Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. Rheumatology Advances in Practice, 2021, 5, rkab059.	0.3	15
10	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
11	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatology, The, 2021, 3, e328-e336.	2.2	52
12	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. Expert Opinion on Orphan Drugs, 2021, 9, 161-173.	0.5	4
13	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. Rheumatology, 2021, 60, 4361-4366.	0.9	15
14	Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters. Journal of Clinical Rheumatology, 2021, 27, e254-e255.	0.5	1
15	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. Lancet Rheumatology, The, 2021, 3, e886-e895.	2.2	15
16	Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. Rheumatology, 2021, 60, e66-e66.	0.9	0
17	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.5	667
18	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	0.9	21

#	ARTICLE	IF	CITATIONS
19	Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 393-399.	0.5	77
20	The role of vascular ultrasound in managing giant cell arteritis in ophthalmology. <i>Survey of Ophthalmology</i> , 2020, 65, 218-226.	1.7	5
21	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	0.9	8
22	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , 2020, 6, e001297.	1.8	29
23	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , 2020, 6, e001417.	1.8	24
24	Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 3717-3726.	0.9	26
25	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. <i>Rheumatology and Therapy</i> , 2020, 7, 793-810.	1.1	30
26	Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA). <i>BMC Rheumatology</i> , 2020, 4, 35.	0.6	13
27	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
28	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
29	Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 171-181.	0.3	13
30	Polymyalgia rheumatica and large vessel vasculitis: a case report. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa049.	0.3	0
31	Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1900-1904.	0.9	6
32	Binocular sight loss: uncommon, yet a devastating complication of GCA. <i>Rheumatology Advances in Practice</i> , 2019, 3, .	0.3	1
33	Update on the role of ultrasound in GCA/LVV and current training options in the UK. <i>Rheumatology</i> , 2019, 58, .	0.9	0
34	"Slope sign": a feature of large vessel vasculitis?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1738-1738.	0.5	16
35	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.5	34
36	Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. <i>Clinical Science</i> , 2019, 133, 839-851.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Glucocorticoid Dosages and Acute Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	2.9	74
38	Response to: "Correspondence to "Slope sign"™: a feature of large vessel vasculitis"™ by Milchert et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216690.	0.5	1
39	THU0286...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
40	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	1.8	56
41	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17
42	A probability score to aid the diagnosis of suspected giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 104-108.	0.4	12
43	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.5	753
44	Current and emerging therapies in large-vessel vasculitis. <i>Rheumatology</i> , 2018, 57, 1513-1524.	0.9	18
45	A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 285-291.	0.9	13
46	91. A journey between the ologists: is it lupus?. <i>Rheumatology Advances in Practice</i> , 2018, 2, .	0.3	0
47	Prevention of glucocorticoid morbidity in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, ii11-ii21.	0.9	34
48	Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises. <i>Journal of Rheumatology</i> , 2018, 45, 1289-1295.	1.0	49
49	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. <i>Eye and Brain</i> , 2018, Volume 10, 1-11.	3.8	9
50	Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group. <i>RMD Open</i> , 2018, 4, e000598.	1.8	155
51	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018, 148, w14588.	0.8	7
52	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. <i>Rheumatology</i> , 2017, 56, kew273.	0.9	138
53	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017, 37, 623-631.	1.5	16
54	Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. <i>RMD Open</i> , 2017, 3, e000426.	1.8	19

#	ARTICLE	IF	CITATIONS
55	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017, 69, 1714-1723.	1.5	18
56	Tocilizumab (Actemra). <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1972-1988.	1.4	193
57	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017, 13, 578-592.	3.5	161
58	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	13.9	974
59	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	1.6	62
60	A case report of neurosarcoidosis successfully treated with an infliximab biosimilar after a relapse while on dual therapy. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 356-357.	0.4	2
61	Characterising those with incident polymyalgia rheumatica in primary care: results from the PMR Cohort Study. <i>Arthritis Research and Therapy</i> , 2016, 18, 200.	1.6	20
62	Ultrasound Compared with Biopsy in the Diagnosis of Suspected Giant Cell Arteritis. <i>Rheumatology</i> , 2016, 55, i37-i37.	0.9	0
63	Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. <i>RMD Open</i> , 2016, 2, e000137.	1.8	36
64	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016, 2, e000282.	1.8	77
65	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.5	258
66	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	1.0	24
67	Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. <i>Rheumatology</i> , 2016, 55, 1466-1476.	0.9	20
68	2015 EULAR/ACR recommendations for polymyalgia rheumatica: the message and next steps. <i>Rheumatology</i> , 2016, 55, 955-956.	0.9	1
69	Emerging therapies in large vessel vasculitis. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 741-746.	0.9	0
70	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2442.	3.8	346
71	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 75-90.	0.8	38
72	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. <i>Health Technology Assessment</i> , 2016, 20, 1-238.	1.3	313

#	ARTICLE	IF	CITATIONS
73	A pragmatic approach to imaging in large vessel vasculitis. Expert Opinion on Orphan Drugs, 2015, 3, 767-775.	0.5	0
74	Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica. RMD Open, 2015, 1, e000095.	1.8	5
75	Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open, 2015, 1, e000100.	1.8	47
76	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. Arthritis Research and Therapy, 2015, 17, 195.	1.6	40
77	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2569-2580.	2.9	146
78	Giant Cell Arteritis: Beyond Corticosteroids. Drugs and Aging, 2015, 32, 591-599.	1.3	6
79	Polymyalgia rheumatica: strategies for efficient practice and quality assurance. Rheumatology International, 2015, 35, 1781-1789.	1.5	6
80	Improved renal function in diabetic patients with acute gout treated with anakinra. Kidney International, 2015, 88, 195-196.	2.6	17
81	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
82	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. Rheumatology, 2015, 55, kev373.	0.9	9
83	Imaging in Giant Cell Arteritis. Current Rheumatology Reports, 2015, 17, 52.	2.1	39
84	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.5	220
85	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2015, 74, 1808-1817.	0.5	74
86	The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Annals of the Rheumatic Diseases, 2015, 74, 129-135.	0.5	149
87	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. PLoS ONE, 2015, 10, e0143970.	1.1	45
88	133.â€fNational Audit on Diagnosis and Management of Polymyalgia Rheumatica. Rheumatology, 2014, 53, i110-i110.	0.9	0
89	12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Rheumatology, 2014, 53, i7-i7.	0.9	3
90	Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases, 2014, 73, 1607-1615.	0.5	125

#	ARTICLE	IF	CITATIONS
91	Investigational Analysis Reveals a Potential Role for Neutrophils in Giant-Cell Arteritis Disease Progression. <i>Circulation Research</i> , 2014, 114, 242-248.	2.0	68
92	P7. Gender differences in health-related quality of life in polymyalgia rheumatica. <i>Rheumatology</i> , 2014, 53, i14-i14.	0.9	1
93	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1362-1368.	0.5	87
94	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1477-1486.	0.5	23
95	Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes. <i>Arthritis Care and Research</i> , 2014, 66, 1799-1807.	1.5	13
96	Apport de l'imagerie dans la pseudo-polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.5	2
97	Contribution of imaging in Polymyalgia Rheumatica. <i>Joint Bone Spine</i> , 2013, 80, 228-229.	0.8	3
98	Imaging indications in polymyalgia rheumatica. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 39-48.	0.3	4
99	Design of the Tocilizumab in Giant Cell Arteritis Trial. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-10.	0.9	96
100	Giant cell arteritis: a review. <i>Eye and Brain</i> , 2013, 5, 23.	3.8	21
101	Treatment of polymyalgia rheumatica. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 211-220.	0.5	1
102	Polymyalgia rheumatica in older adults. <i>Aging Health</i> , 2013, 9, 483-495.	0.3	4
103	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.5	451
104	Diagnosis and management of polymyalgia rheumatica. <i>British Journal of General Practice</i> , 2012, 62, 275-276.	0.7	10
105	Diagnosis and assessment of polymyalgia rheumatica: a step forward. <i>Aging Health</i> , 2012, 8, 395-397.	0.3	2
106	Diagnosis and management of giant cell arteritis. <i>British Journal of General Practice</i> , 2012, 62, 329-330.	0.7	28
107	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	1.0	64
108	The epidemiology of polymyalgia rheumatica in primary care: a research protocol. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 102.	0.8	18

#	ARTICLE	IF	CITATIONS
109	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
110	Giant cell arteritis. <i>BMJ: British Medical Journal</i> , 2011, 342, d3019-d3019.	2.4	11
111	Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. <i>Aging Health</i> , 2011, 7, 633-645.	0.3	19
112	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 447-453.	0.5	81
113	Delays in recognition and management of giant cell arteritis: results from a retrospective audit. <i>Clinical Rheumatology</i> , 2011, 30, 259-262.	1.0	47
114	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. <i>Rheumatology</i> , 2011, 50, 2014-2022.	0.9	31
115	Clinical observations on the significance of raised cardiac troponin-T in patients with myositis of varying etiologies seen in rheumatology practice. <i>Clinical Rheumatology</i> , 2010, 29, 1107-1111.	1.0	11
116	Metabolic and Crystal Arthropathies [70-72]: 70. Single Intramuscular Depot Methylprednisolone Injection: A Convenient, Efficacious and Safe Treatment for Gouty Arthritis in an Inpatient Setting. <i>Rheumatology</i> , 2010, 49, i59-i61.	0.9	0
117	Concise guidance: diagnosis and management of polymyalgia rheumatica. <i>Clinical Medicine</i> , 2010, 10, 270-274.	0.8	15
118	Current understanding and management of giant cell arteritis and polymyalgia rheumatica. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 913-928.	1.3	24
119	Concise guidance: diagnosis and management of giant cell arteritis. <i>Clinical Medicine</i> , 2010, 10, 381-386.	0.8	68
120	BSR and BHPR guidelines for the management of giant cell arteritis. <i>Rheumatology</i> , 2010, 49, 1594-1597.	0.9	410
121	BSR and BHPR guidelines for the management of polymyalgia rheumatica. <i>Rheumatology</i> , 2010, 49, 186-190.	0.9	213
122	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. <i>International Journal of Rheumatology</i> , 2009, 2009, 1-5.	0.9	23
123	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. <i>Modern Rheumatology</i> , 2009, 19, 53-56.	0.9	31
124	Treatment and outcomes of large vessel arteritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 325-337.	1.4	39
125	Improvement in diagnosis and management of musculoskeletal conditions with one-stop clinic-based ultrasonography. <i>Modern Rheumatology</i> , 2009, 19, 53-56.	0.9	20
126	Neuro-ophthalmic complications in giant cell arteritis. <i>Current Allergy and Asthma Reports</i> , 2008, 8, 323-330.	2.4	25



#	ARTICLE	IF	CITATIONS
127	Musculoskeletal ultrasonography: to keep pace with progress or be left behind?. International Journal of Rheumatic Diseases, 2008, 11, 109-117.	0.9	3
128	Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Family Practice, 2008, 25, 328-333.	0.8	55
129	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. Journal of Rheumatology, 2008, 35, 270-7.	1.0	61
130	Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis and Rheumatism, 2007, 57, 803-809.	6.7	122
131	Polymyalgia rheumatica and giant cell arteritis. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 0:2	0.2	8
132	Polymyalgia rheumatica: The mess we are now in and what we need to do about it. Arthritis and Rheumatism, 2006, 55, 518-520.	6.7	37
133	038â€fHow Common are Giant Cell Arteritis Symptoms in Patients with Polymyalgia Rheumatica? Results from an Incident Primary Care Cohort. Rheumatology, 0, , .	0.9	0